Canadian Stock Exchange:PHRM.CN

TORONTO, July 18, 2023 (GLOBE NEWSWIRE) -- PharmaTher Holdings Ltd. (the “Company” or “PharmaTher”) (OTCQB: PHRRF) (CSE: PHRM), a commercial-focused specialty pharmaceutical company, is pleased to announce that it has successfully…

<!-- Name:DistributionId Value:8797519 --> <!-- Name:EnableQuoteCarouselOnPnr Value:False --> <!-- Name:IcbCode Value:4577 -->…

<!-- Name:DistributionId Value:8744316 --> <!-- Name:EnableQuoteCarouselOnPnr Value:False --> <!-- Name:IcbCode Value:4577 -->…

<!-- Name:DistributionId Value:8741437 --> <!-- Name:EnableQuoteCarouselOnPnr Value:False --> <!-- Name:IcbCode Value:4577 -->…

<!-- Name:DistributionId Value:8740966 --> <!-- Name:EnableQuoteCarouselOnPnr Value:False --> <!-- Name:IcbCode Value:4577 -->…

KETABET™ (Ketamine and Betaine) shown effectiveness as measured by the Clinician Administered Dissociative States Scale Study results are adequate to give an effect size in powering a placebo-controlled clinical study PharmaTher planning…

Adds to PharmaTher’s existing FDA orphan drug portfolio with amyotrophic lateral sclerosis and complex regional pain syndromeStrengthens commitment to treat rare disorders and life-threatening conditions with ketamine TORONTO, Nov. 24,…

TORONTO, Sept. 29, 2021 (GLOBE NEWSWIRE) -- PharmaTher Holdings Ltd. (the “Company” or “PharmaTher”) (OTCQB: PHRRF) (CSE: PHRM), a clinical-stage psychedelics biotech company, today announced that Dr. Thomas Laughren has been retained by…